[
  {
    "ts": null,
    "headline": "Novavax Inc (NVAX) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ...",
    "summary": "Novavax Inc (NVAX) reports a 65% revenue increase and secures major partnerships, despite facing regulatory uncertainties and strategic challenges.",
    "url": "https://finnhub.io/api/news?id=6cae21dd5c978834e4e03f7fe37c026b42c3c313f955ec677694854386b74dfe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772140304,
      "headline": "Novavax Inc (NVAX) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ...",
      "id": 139239917,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Novavax Inc (NVAX) reports a 65% revenue increase and secures major partnerships, despite facing regulatory uncertainties and strategic challenges.",
      "url": "https://finnhub.io/api/news?id=6cae21dd5c978834e4e03f7fe37c026b42c3c313f955ec677694854386b74dfe"
    }
  },
  {
    "ts": null,
    "headline": "Top Research Reports for Meta, Netflix & Pfizer",
    "summary": "Meta Platforms, Netflix and Pfizer lead fresh research as AI bets, bold 2030 goals and patent cliffs shape their outlooks.",
    "url": "https://finnhub.io/api/news?id=4000e9c68c4d77258af6f41ca1a676449a6460f1b71dc79741eca0de73012d58",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772140260,
      "headline": "Top Research Reports for Meta, Netflix & Pfizer",
      "id": 139240856,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Meta Platforms, Netflix and Pfizer lead fresh research as AI bets, bold 2030 goals and patent cliffs shape their outlooks.",
      "url": "https://finnhub.io/api/news?id=4000e9c68c4d77258af6f41ca1a676449a6460f1b71dc79741eca0de73012d58"
    }
  },
  {
    "ts": null,
    "headline": "This US Bancorp Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=856bd38e9756353b5c1ab292aa5994b083a3517663c2a6a39277c0e0ed69cc0e",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772116649,
      "headline": "This US Bancorp Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday",
      "id": 139247582,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/26/Richfield--Mn---usa---June-21--2014-Us-B_0.jpeg?width=2048&height=1536",
      "related": "PFE",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=856bd38e9756353b5c1ab292aa5994b083a3517663c2a6a39277c0e0ed69cc0e"
    }
  },
  {
    "ts": null,
    "headline": "Novavax shares subdued despite earnings, revenue beat",
    "summary": "Investing.com -- Novavax Inc. (NASDAQ:NVAX) reported fourth quarter results that exceeded analyst expectations. Shares initially fell premarket, but now trade around 0.7% higher.",
    "url": "https://finnhub.io/api/news?id=ede965c6e8c99a46c3273f234988bd82b71243e0abcc4194e30634b407fde4c7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772113560,
      "headline": "Novavax shares subdued despite earnings, revenue beat",
      "id": 139232253,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Investing.com -- Novavax Inc. (NASDAQ:NVAX) reported fourth quarter results that exceeded analyst expectations. Shares initially fell premarket, but now trade around 0.7% higher.",
      "url": "https://finnhub.io/api/news?id=ede965c6e8c99a46c3273f234988bd82b71243e0abcc4194e30634b407fde4c7"
    }
  },
  {
    "ts": null,
    "headline": "Novavax, Inc. Q4 2025 Earnings Call Summary",
    "summary": "Moby summary of Novavax, Inc.'s Q4 2025 earnings call",
    "url": "https://finnhub.io/api/news?id=dd881b7a9bf8506e2ddc9ef3d6619a864e01f351af4630a4415518f71a3ecf53",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772112600,
      "headline": "Novavax, Inc. Q4 2025 Earnings Call Summary",
      "id": 139239918,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Moby summary of Novavax, Inc.'s Q4 2025 earnings call",
      "url": "https://finnhub.io/api/news?id=dd881b7a9bf8506e2ddc9ef3d6619a864e01f351af4630a4415518f71a3ecf53"
    }
  },
  {
    "ts": null,
    "headline": "Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights",
    "summary": "Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and year ended December 31, 2025.",
    "url": "https://finnhub.io/api/news?id=c5a5b1a656dc5ce0e85a9461a1a0905f61ff8cee9ddf5823b47a34d63911873b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772110800,
      "headline": "Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights",
      "id": 139232254,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and year ended December 31, 2025.",
      "url": "https://finnhub.io/api/news?id=c5a5b1a656dc5ce0e85a9461a1a0905f61ff8cee9ddf5823b47a34d63911873b"
    }
  },
  {
    "ts": null,
    "headline": "Boehringer drug approved in 44 days; BioMarin shelves Roctavian",
    "summary": "Boehringer’s lung cancer medicine Hernexeos is the second “national priority” voucher winner to gain a speedy approval. Elsewhere, a landmark gene therapy was withdrawn and a Pfizer deal paid dividends.",
    "url": "https://finnhub.io/api/news?id=d62f74c34b16f5c9be906fcceae36dbf6fae9abe0aa60cb4929b25d89f9ca42f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772098740,
      "headline": "Boehringer drug approved in 44 days; BioMarin shelves Roctavian",
      "id": 139250074,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Boehringer’s lung cancer medicine Hernexeos is the second “national priority” voucher winner to gain a speedy approval. Elsewhere, a landmark gene therapy was withdrawn and a Pfizer deal paid dividends.",
      "url": "https://finnhub.io/api/news?id=d62f74c34b16f5c9be906fcceae36dbf6fae9abe0aa60cb4929b25d89f9ca42f"
    }
  },
  {
    "ts": null,
    "headline": "This Pfizer Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=ee97229b03c82558c6b730e573cd68dc7fc880c2c23e1ce1f678c82082ce440b",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772098683,
      "headline": "This Pfizer Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday",
      "id": 139231907,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/26/Franklin---April-21--2024-Pfizer-Site-Ma.jpeg?width=2048&height=1536",
      "related": "PFE",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=ee97229b03c82558c6b730e573cd68dc7fc880c2c23e1ce1f678c82082ce440b"
    }
  },
  {
    "ts": null,
    "headline": "Cardiff Oncology Spotlights Onvansertib Data at Oppenheimer: 72% ORR in RAS-Mutant mCRC",
    "summary": "Cardiff Oncology (NASDAQ:CRDF) used an appearance at Oppenheimer’s 36th Annual Healthcare Conference to highlight updated clinical results and its development plans for onvansertib, an oral, highly selective polo-like kinase 1 (PLK1) inhibitor being studied in RAS-mutated metastatic colorectal cance",
    "url": "https://finnhub.io/api/news?id=927f9f9f744a4b3e60351bc1c095c227badc30c74cb86c82049fab8f4d9bb01b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772098358,
      "headline": "Cardiff Oncology Spotlights Onvansertib Data at Oppenheimer: 72% ORR in RAS-Mutant mCRC",
      "id": 139237174,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Cardiff Oncology (NASDAQ:CRDF) used an appearance at Oppenheimer’s 36th Annual Healthcare Conference to highlight updated clinical results and its development plans for onvansertib, an oral, highly selective polo-like kinase 1 (PLK1) inhibitor being studied in RAS-mutated metastatic colorectal cance",
      "url": "https://finnhub.io/api/news?id=927f9f9f744a4b3e60351bc1c095c227badc30c74cb86c82049fab8f4d9bb01b"
    }
  },
  {
    "ts": null,
    "headline": "5 'Safer' Dividend Buys In Barron's 23 Better February Bets Than T-Bills",
    "summary": "5 'Safer' Dividend Buys In Barron's 23 Better February Bets Than T-Bills",
    "url": "https://finnhub.io/api/news?id=eeb39e7ab0f575e497486bf4334ce8d29b0026e5fdbb993650ffb8829709eb8d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772092081,
      "headline": "5 'Safer' Dividend Buys In Barron's 23 Better February Bets Than T-Bills",
      "id": 139231292,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=eeb39e7ab0f575e497486bf4334ce8d29b0026e5fdbb993650ffb8829709eb8d"
    }
  },
  {
    "ts": null,
    "headline": "RBC Capital Initiates Pfizer (PFE) with $25 Target, Warns of Structural Revenue Headwinds",
    "summary": "Pfizer Inc. (NYSE:PFE) is included among the 14 Best Affordable Dividend Stocks to Buy According to Analysts. On February 25, RBC Capital initiated coverage of Pfizer Inc. (NYSE:PFE) with an Underperform rating and a $25 price target. The firm said its outlook reflects an “insurmountable” $15B-$20B revenue decline expected through 2030, with limited visibility into […]",
    "url": "https://finnhub.io/api/news?id=a1bf82326f003ba5c9d8cd81ed3b8ac627d07df643486ba2fea237878573c76e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772074209,
      "headline": "RBC Capital Initiates Pfizer (PFE) with $25 Target, Warns of Structural Revenue Headwinds",
      "id": 139227936,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is included among the 14 Best Affordable Dividend Stocks to Buy According to Analysts. On February 25, RBC Capital initiated coverage of Pfizer Inc. (NYSE:PFE) with an Underperform rating and a $25 price target. The firm said its outlook reflects an “insurmountable” $15B-$20B revenue decline expected through 2030, with limited visibility into […]",
      "url": "https://finnhub.io/api/news?id=a1bf82326f003ba5c9d8cd81ed3b8ac627d07df643486ba2fea237878573c76e"
    }
  }
]